- Cocrystal Pharma Inc COCP has submitted a pre-Investigational New Drug (IND) briefing package to the FDA for its broad-spectrum protease inhibitor CDI-45205 in COVID-19.
- FDA's response is expected to provide greater clarity and guidance on designing Phase 1 and Phase 2 trials for CDI-45205.
- Related Link: Cocrystal Pharma's Preclinical Protease Inhibitor Effective Against Original, Two Variant COVID-19 Strains.
- CDI-45205 is among protease inhibitors obtained under an exclusive license agreement with Kansas State University Research Foundation (KSURF) in 2020.
- CDI-45205 and several analogs showed potent in vitro activity against the variants, surpassing the activity observed with the original Wuhan strain.
- Related content: Benzinga's Full FDA Calendar.
- Price Action: COCP shares are up 5.92% at $0.95 on Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
